Literature DB >> 32375106

Identification and characterization of citalopram new metabolites with the use of UHPLC-Q-TOF technique: In silico toxicity assessment of the identified transformation products.

Maciej Gawlik1, Jakub Trawiński1, Robert Skibiński2.   

Abstract

In this study the metabolite profiling of citalopram with the use of human liver microsomes as well as the complementary photocatalytic method were established. This strategy allowed the detection of five metabolites of citalopram including 3-hydroxycitalopram and 3-oxocitalopram which were found as a new and not previously described metabolites of this drug The photocatalytic simulation of metabolism was carried out using tungsten (VI) oxide nanopowders with the different particle sizes, which allowed to examine the effect of this photocatalyst parameter on the mapping of metabolic processes. The accurate characterization of all observed structures was possible due to the use of ultra-high-pressure liquid chromatography and high-resolution mass spectrometry combined system as a highly useful technique in drug metabolism studies. In order to perform the toxicity prediction of citalopram and its metabolites, the acute toxicity to rodents, as well as genotoxicity, carcinogenicity, developmental toxicity and receptor-mediated toxicity was calculated basing on the in silico tools.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug metabolism; In silico toxicity; Mass spectrometry; PCA; Photocatalysis

Year:  2020        PMID: 32375106     DOI: 10.1016/j.jpba.2020.113299

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Dental workers in front-line of COVID-19: an in silico evaluation targeting their prevention.

Authors:  Pedro Henrique Sette-DE-Souza; Moan Jéfter Fernandes Costa; Lucas Amaral-Machado; Fábio Andrey da Costa Araújo; Adauto Trigueiro Almeida Filho; Luiza Rayanna Amorim de Lima
Journal:  J Appl Oral Sci       Date:  2021-03-26       Impact factor: 2.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.